Document is current

Article History

Received: 25 July 2023

Accepted: 2 August 2023

First Online: 31 August 2023

Declarations

:

: VC reports personal fees from Roche, Bristol Myers Squibb, Merck Sharp & Dohme, AstraZeneca, Takeda, Pfizer, Lilly, AMGEN and Sanofi and non-financial support from Takeda, Roche and Merck Sharp & Dohme outside the submitted work. MC reports personal fees from Novartis, AstraZeneca, Boehringer-Ingelheim, Roche, Bristol Myers Squibb, Lilly, Merck Sharp & Dohme, Takeda, Pfizer, Kyowa, Sanofi, Jansen, Pierre-Fabre and Novocure, outside the submitted work. MD reports personal fees from AstraZeneca, Bristol-Myers Squibb, Merck Sharp & Dohme, Pfizer, Roche, Takeda and non-financial support from AstraZeneca, Merck Sharp & Dohme and Takeda, outside the submitted work. MRGC reports personal fees from AstraZeneca, Roche, Lilly, Novartis, Merck Sharp & Dohme, Takeda and Pfizer, outside the submitted work. MG reports personal fees from Roche, Merck Sharp & Dohme and Takeda and non-financial support from Takeda and Merck Sharp & Dohme, outside the submitted work. FHT reports personal fees from Bristol-Myers Squibb, Medtronic, AstraZeneca, Roche and Johnson & Johnson, outside the submitted work. BM reports personal fees from Roche, Bristol-Myers Squibb, Merck Sharp & Dohme, Boehringer Ingelheim, Takeda and AbbVie and non-financial support from Roche, Pfizer, Merck Serono, Boehringer-Ingelheim, AstraZeneca, outside the submitted work. EN reports personal fees from Roche, Bristol Myers Squibb, Merck Sharp Dohme, Sanofi, Pfizer, Lilly, Amgen, Janssen, Boehringer-Ingelheim, AstraZeneca, Takeda, Qiagen, Mirati, Bayer, Merck-Serono, Daiichi-Sankyo and Pierre Fabre and non-financial support from Takeda, Merck Sharp & Dohme, AstraZeneca and Roche, outside the submitted work. IGS reports personal fees from Takeda, Sanofi, Bristol-Myers Squibb, Roche, Novartis, Merck Sharp & Dohme, AstraZeneca and Pfizer and non-financial from Takeda, Roche, Novartis, Merck Sharp & Dohme, AstraZeneca, Pfizer and Lilly, outside the submitted work. MP reports grants from AstraZeneca, Roche, BMS, Boehringer-Ingelheim and Takeda; personal fees from AstraZeneca, Bristol-Myers Squibb, Boehringer-Ingelheim, Celgene, Merck Sharp & Dohme, Roche, Takeda, and Thermo-Fisher, outside the submitted work. All remaining authors have declared no conflicts of interest.

: This is not a study with patients or animals. It is a review, it does not require approval by an ethical committee or informed consent from patients.